Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ambit Biosciences Inc.

Division of Daiichi Sankyo Co. Ltd.
www.ambitbio.com

Latest From Ambit Biosciences Inc.

Daiichi Sankyo Lays Out Priorities As It Pursues Oncology Ambitions

Daiichi Sankyo says it is “committed to a major transformation in oncology” as it prioritizes and pursues projects in this field under a new team leader, who chose to highlight unique antibody-drug conjugate technology and the acute myeloid leukemia franchise at a recent R&D Day in Tokyo.

Research & Development Companies

APPOINTMENTS: Valeant, Gilead, Editas, Daiichi, Scancell, PhaseRx, Clintec, Acadia

This week’s announcements include Valeant’s appointment of an executive vice president finance, Editas Medicine’s appointment of a chief scientific officer, Clintec’s appointment of AstraZeneca’s former global research director and various board appointments by Acadia, Scancell, PhaseRx and Gilead.

Appointments BioPharmaceutical

Daiichi Sankyo Hoping Its Post-Olmesartan Plan Comes Together

"I love it when a plan comes together," Hannibal Smith of TV show The A-Team used to say, a catchphrase which Daiichi Sankyo will be hoping is appropriate in around five years' time as it looks back on the results of its new mid-term strategy.

BioPharmaceutical Japan

Mirna Therapeutics Appoints CFO

Mirna Therapeutics, which is developing a broad pipeline of microRNA-based oncology therapeutics, has appointed Alan Fuhrman as chief financial officer. He was most recently the CFO of Ambit Biosciences, where he helped lead the company through its initial public offering and then its sale to Daiichi Sankyo in 2014.

Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Inflammation
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Daiichi Sankyo Co. Ltd.
  • Senior Management
  • Michael A Martino, Pres. & CEO
    Alan Fuhrman, CFO
  • Contact Info
  • Ambit Biosciences Inc.
    Phone: (858) 334-2100
    4215 Sorrento Valley Blvd.
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register